Diagnostic usefulness of an amino acid tracer, α-[N-methyl- 11C]-methylaminoisobutyric acid (11C-MeAIB), in the PET diagnosis of chest malignancies

Annals of Nuclear Medicine

Volumn 27, Issue 9, 2013, Pages 808-821

  Nishii, Ryuichi ^a,c   Higashi, Tatsuya ^a   Kagawa, Shinya ^a   Kishibe, Yoshihiko ^a   Takahashi, Masaaki ^a   Yamauchi, Hiroshi ^a   Motoyama, Hideki ^b   Kawakami, Kenzo ^b   Nakaoku, Takashi ^b   Nohara, Jun ^b   Okamura, Misato ^b   Watanabe, Toshiki ^b   Nakatani, Koichi ^b   Nagamachi, Shigeki ^c   Tamura, Shozo ^c   Kawai, Keiichi ^d   Kobayashi, Masato ^d  

^a Shiga Medical Center Research Institute   (Japan)

^b Shiga Medical Center   (Japan)

^c UNIVERSITY OF MIYAZAKI   (Japan)

^d KANAZAWA UNIVERSITY   (Japan)

Author keywords

Amino acid tracer; Fluorodeoxyglucose; Lung cancer; Lymphadenopathy; Methylaminoisobutyric acid; Positron emission tomography; Sarcoidosis

Indexed keywords

ALPHA(N METHYL CARBON)METHYLAMINOISOBUTYRIC ACID C 11; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; COLON CANCER; COLON METASTASIS; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; GRANULOMATOUS INFLAMMATION; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG CANCER; LUNG NODULE; LYMPH NODE BIOPSY; LYMPHADENOPATHY; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MEDIASTINAL SARCOID LYMPHADENOPATHY; MEDIASTINUM MASS; MULTIDETECTOR COMPUTED TOMOGRAPHY; PAPILLARY ADENOCARCINOMA; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SARCOIDOSIS; SENSITIVITY AND SPECIFICITY; WHOLE BODY PET;

ADULT; AGED; AGED, 80 AND OVER; BETA-ALANINE; BIOLOGICAL TRANSPORT; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; ISOBUTYRATES; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; THORACIC NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84890311195     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-013-0750-4     Document Type: Article

References (28)

1. Poeppel TD, Krause BJ, Heusner TA, Boy C, Bockisch A, Antoch G. PET/CT for the staging and follow-up of patients with malignancies. Eur J Radiol. 2009;70(3):382-92.
2. Metser U, Even-Sapir E. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT. Semin Nucl Med. 2007;37(3):206-22.
3. Higashi T, Saga T, Nakamoto Y, Ishimori T, Fujimoto K, Doi R, Imamura M, Konishi J. Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) - usefulness and limitations in "clinical reality". Ann Nucl Med. 2003;17(4):261-79 (review).
4. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics. 1999;19(1):61-77 (review).
5. Chang JM, Lee HJ, Goo JM, Lee HY, Lee JJ, Chung JK, Im JG. False positive and false negative FDG-PET scans in various thoracic diseases. Korean J Radiol. 2006;7:57-69 (review).
6. Hu M, Han A, Xing L, Yang W, Fu Z, Huang C, et al. Value of dual-time-point FDG PET/CT for mediastinal nodal staging in non-small-cell lung cancer patients with lung comorbidity. Clin Nucl Med. 2011;36:429-33.
7. Deppen S, Putnam JB Jr, Andrade G, Speroff T, Nesbitt JC, Lambright ES, et al. Accuracy of FDG-PET to diagnose lung cancer in a region of endemic granulomatous disease. Ann Thorac Surg. 2011;92:428-32.
8. 18F-FDG PET/CT in mediastinal lymph node staging of non-small-cell lung cancer in a tuberculosis-endemic country: consideration of lymph node calcification and distribution pattern to improve specificity. Eur J Nucl Med Mol Imaging. 2009;36:1794-802.
9. Antoni G, Långström B. Radiopharmaceuticals: molecular imaging using positron emission tomography. Handb Exp Pharmacol. 2008;(185 Pt 1):177-201. Review.
10. Wadsak W, Mitterhauser M. Basics and principles of radiopharmaceuticals for PET/CT. Eur J Radiol. 2010;73(3):461-9 (review).
11. Jager PL, Vaalburg W, Pruim J, de Vries EG, Langen KJ, Piers DA. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med. 2001;42(3):432-45 (review).
12. Leskinen-Kallio S, Ruotsalainen U, Någren K, Teräs M, Joensuu H. Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: a PET study. J Nucl Med. 1991;32(6):1211-8.
13. 11C]-l-methionine as a protein synthesis marker in the pancreas. Ann Nucl Med. 1990;4(1):29-33.
14. van Waarde A, Jager PL, Ishiwata K, Dierckx RA, Elsinga PH. Comparison of sigma-ligands and metabolic PET tracers for differentiating tumor from inflammation. J Nucl Med. 2006;47(1):150-4.
15. Yamada Y, Uchida Y, Tatsumi K, Yamaguchi T, Kimura H, Kitahara H, et al. Fluorine-18-fluorodeoxyglucose and carbon-11-methionine evaluation of lymphadenopathy in sarcoidosis. J Nucl Med. 1998;39(7):1160-6.
16. 11C] methylaminoisobutyric acid, a tracer for PET studies on system A amino acid transport in vivo. Eur J Nucl Med. 2001;28(7):847-54.
17. Christensen HN. Role of amino acid transport and countertransport in nutrition and metabolism. Physiol Rev. 1990;70(1):43-77 (review).
18. 11C]methylaminoisobutyrate (MEAIB) and PET. Eur J Nucl Med Mol Imaging. 2002;29(11):1485-91.
19. 11C]alpha-methylaminoisobutyric acid in untreated head and neck cancer studied by PET. Eur J Nucl Med Mol Imaging. 2003;30(1):72-7.
20. 11C]Methyl Triflate and HPLC metabolite analysis of plasma samples after intravenous administration in man. J Label Cpd Radiopharm. 2000;43:1013-21.
21. 18F-fluorodeoxyglucose in sarcoidosis patients. Chest. 2007;131:1019-27.
22. Inoue T, Tomiyoshi K, Higuchi T, Ahmed K, Sarwar M, Woyagi K, et al. Biodistribution studies on L-[3-18F] fluoro-alpha-methyltyrosine: a potential tumor-detecting agent. J Nucl Med. 1998;39:663-7.
23. Kanegae K, Nakano I, Kimura K, Kaji H, Kuge Y, Shiga T, et al. Comparison of MET-PET and FDG-PET for differentiation between benign lesions and lung cancer in pneumoconiosis. Ann Nucl Med. 2007;21(6):331-7.
24. Sasaki M, Kuwabara Y, Yoshida T, Nakagawa M, Koga H, Hayashi K, et al. Comparison of MET-PET and FDG-PET for differentiation between benign lesions and malignant tumors of the lung. Ann Nucl Med. 2001;15(5):425-31.
25. 18F-FDG-PET. Ann Nucl Med. 2008;22(6):533-8.
26. Kashani-Sabet M, Scanlon KJ. Drug selectivity and membrane transport properties of normal human lymphocytes. Chemotherapy. 1989;35(5):363-72.
27. del Amo EM, Urtti A, Yliperttula M. Pharmacokinetic role of L-type amino acid transporters LAT1 and LAT2. Eur J Pharm Sci. 2008;35(3):161-74.
28. Wu Y, Shen D, Chen Z, Clayton S, Vadgama JV. Taxol induced apoptosis regulates amino acid transport in breast cancer cells. Apoptosis. 2007;12(3):593-612.